biotech / news / / FinanzNachrichten
Metabolic Dysfunction-associated Steatohepatitis (MASH) affects an estimated 250 million people globally.
ESSENCE trial data confirm semaglutide's favorable hepatic safety profile in MASH patients, regardless of characteristics.
KEY POINTS
- First dedicated data for Japanese and menopausal women show semaglutide's liver benefits extend across diverse populations.
- ESSENCE Menopause subgroup analysis provides targeted evidence for a group historically excluded from liver trials.
- Real-world data reveal significant quality-of-life impairment, cost, and underdiagnosis in MASH, highlighted at EASL 2026.
COMPANIES
Summarized by Newsio from FinanzNachrichten. How we summarize →